Abstract

Standard network meta‐analysis and indirect comparisons combine aggregate data from multiple studies on treatments of interest, assuming that any factors that interact with treatment effects (effect modifiers) are balanced across populations. Population adjustment methods such as multilevel network meta‐regression (ML‐NMR), matching‐adjusted indirect comparison (MAIC), and simulated treatment comparison (STC) relax this assumption using individual patient data from one or more studies, and are becoming increasingly prevalent in health technology appraisals and the applied literature. Motivated by an applied example and two recent reviews of applications, we undertook an extensive simulation study to assess the performance of these methods in a range of scenarios under various failures of assumptions. We investigated the impact of varying sample size, missing effect modifiers, strength of effect modification and validity of the shared effect modifier assumption, validity of extrapolation and varying between‐study overlap, and different covariate distributions and correlations. ML‐NMR and STC performed similarly, eliminating bias when the requisite assumptions were met. Serious concerns are raised for MAIC, which performed poorly in nearly all simulation scenarios and may even increase bias compared with standard indirect comparisons. All methods incur bias when an effect modifier is missing, highlighting the necessity of careful selection of potential effect modifiers prior to analysis. When all effect modifiers are included, ML‐NMR and STC are robust techniques for population adjustment. ML‐NMR offers additional advantages over MAIC and STC, including extending to larger treatment networks and producing estimates in any target population, making this an attractive choice in a variety of scenarios.

Highlights

  • Indirect comparison and network meta-analysis (NMA) are standard approaches for producing pooled estimates of relative treatment effects for multiple treatments from multiple randomized controlled trials, where the treatments of interest may not have all been compared in the same randomized controlled trial, but instead form a connected network of treatment comparisons.[1,2,3,4,5,6] For example, we may have a scenario where trials of treatments A vs B and A vs C are available, but there are no trials comparing B vs C

  • In the aggregate data (AgD) study we only have marginal covariate information; the joint covariate distribution f (AC)(x) in the AgD study is assumed to have the same form of marginal distributions and covariate correlations as in the individual patient data (IPD) study, an assumption that we investigate in scenarios g, h, and i (Section 6.6)

  • We have investigated the performance of multilevel network meta-regression (ML-NMR) in comparison with current population adjustment methods (MAIC and simulated treatment comparison (STC)) in a wide range of scenarios, including varying sample sizes, strength of effect modification, overlap between studies, and joint covariate distributions

Read more

Summary

Introduction

Indirect comparison and network meta-analysis (NMA) are standard approaches for producing pooled estimates of relative treatment effects for multiple treatments from multiple randomized controlled trials, where the treatments of interest may not have all been compared in the same randomized controlled trial, but instead form a connected network of treatment comparisons.[1,2,3,4,5,6] For example, we may have a scenario (illustrated in Figure 1) where trials of treatments A vs B and A vs C are available, but there are no trials comparing B vs C. An indirect comparison for the B vs C treatment effect can be obtained via the common comparator A. NMA is the generalization of indirect comparisons to more complex networks of treatment comparisons. Health technology assessments, such as those conducted by the National Institute for Health and Care Excellence in the United Kingdom, require companies to submit evidence on the clinical and cost effectiveness of their treatment compared with other relevant treatments. Indirect comparisons and NMA are routinely used as part of the health technology assessment process, since the available trial evidence may not necessarily include a single head-to-head study of all of the relevant treatment options, and is likely to instead consist of several studies each comparing a subset of treatments

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call